SMTL ID : 6yid.2 (1 other biounit)

Crystal structure of ULK2 in complex with SBI-0206965

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.70 Å

Oligo State

homo-dimer

Ligands

2 x EDJ: 2-({5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}oxy)-N-methylbenzene-1-carboximidic acid(Non-covalent)

EDJ.1: 15 residues within 4Å: Chain A: V.19, G.20, V.27, A.41, K.43, M.89, E.90, Y.91, C.92, N.93, G.95, D.96, Q.139, N.140, L.142 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:V.19, A:V.27 Hydrogen bonds: A:K.43, A:C.92, A:C.92 EDJ.2: 15 residues within 4Å: Chain B: V.19, G.20, H.21, V.27, A.41, K.43, M.89, E.90, Y.91, C.92, G.95, Q.139, N.140, L.142, A.161 4 PLIP interactions: 4 interactions with chain B Hydrophobic interactions: B:V.27 Hydrogen bonds: B:K.43, B:C.92, B:C.92

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ren, H. et al., Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. J.Med.Chem. (2020)

Release Date

2020-06-17

Peptides

Serine/threonine-protein kinase ULK2: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

Serine/threonine-protein kinase ULK2

Related Entries With Identical Sequence